Request Sample Inquiry
Oncolytic Virus Immunotherapy Market

Oncolytic Virus Immunotherapy Market

Oncolytic Virus Immunotherapy Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

147

Base Year:

2022

Date

Sep - 2023

Format:

PDF XLS PPT

Report Code:

VMR-2287

Segments Covered
  • By Product Type By Product Type Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Vesicular Stomatitis Virus, Other Product Types
  • By Application By Application Melanoma, Prostate Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Other Applications
  • By End User By End User Hospitals, Specialty Clinics, Cancer Research Institutes
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 100 Million
Revenue 2030Revenue 2030: USD 615.39 Million
Revenue CAGRRevenue CAGR (2023 - 2030): 25.5%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Oncolytic Virus Immunotherapy Market - Segment Analysis
    1. Overview
    2. Global Oncolytic Virus Immunotherapy Market, 2016 - 2028 (USD Million)
    3. Global Oncolytic Virus Immunotherapy Market - by Product Type
      1. By Herpes Simplex Virus
      2. By Adenovirus
      3. By Vaccinia Virus
      4. By Vesicular Stomatitis Virus
      5. By Other Product Types
    4. Global Oncolytic Virus Immunotherapy Market - by Application
      1. By Melanoma
      2. By Prostate Cancer
      3. By Ovarian Cancer
      4. By Lung Cancer
      5. By Breast Cancer
      6. By Other Applications
    5. Global Oncolytic Virus Immunotherapy Market - by End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Research Institutes
    6. Global Oncolytic Virus Immunotherapy Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    7. Market comparative analysis
  4. North America Oncolytic Virus Immunotherapy Market - Segment Analysis
    1. Overview
    2. North America Oncolytic Virus Immunotherapy Market, 2016 - 2028 (USD Million)
    3. North America Oncolytic Virus Immunotherapy Market, by Product Type
      1. By Herpes Simplex Virus
      2. By Adenovirus
      3. By Vaccinia Virus
      4. By Vesicular Stomatitis Virus
      5. By Other Product Types
    4. North America Oncolytic Virus Immunotherapy Market, by Application
      1. By Melanoma
      2. By Prostate Cancer
      3. By Ovarian Cancer
      4. By Lung Cancer
      5. By Breast Cancer
      6. By Other Applications
    5. North America Oncolytic Virus Immunotherapy Market, by End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Research Institutes
    6. North America Oncolytic Virus Immunotherapy Market, by Country
      1. U.S.
        1. U.S. Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. U.S. Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. U.S. Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      2. Canada
        1. Canada Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Canada Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Canada Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      3. Mexico
        1. Mexico Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Mexico Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Mexico Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
  5. Europe Oncolytic Virus Immunotherapy Market - Segment Analysis
    1. Overview
    2. Europe Oncolytic Virus Immunotherapy Market, 2016 - 2028 (USD Million)
    3. Europe Oncolytic Virus Immunotherapy Market, by Product Type
      1. By Herpes Simplex Virus
      2. By Adenovirus
      3. By Vaccinia Virus
      4. By Vesicular Stomatitis Virus
      5. By Other Product Types
    4. Europe Oncolytic Virus Immunotherapy Market, by Application
      1. By Melanoma
      2. By Prostate Cancer
      3. By Ovarian Cancer
      4. By Lung Cancer
      5. By Breast Cancer
      6. By Other Applications
    5. Europe Oncolytic Virus Immunotherapy Market, by End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Research Institutes
    6. Europe Oncolytic Virus Immunotherapy Market, by Country
      1. Germany
        1. Germany Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Germany Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Germany Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      2. UK
        1. UK Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. UK Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. UK Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      3. France
        1. France Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. France Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. France Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      4. Spain
        1. Spain Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Spain Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Spain Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      5. Italy
        1. Italy Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Italy Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Italy Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      6. BENELUX
        1. BENELUX Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. BENELUX Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. BENELUX Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      7. Rest of Europe
        1. Rest Of Europe Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Rest Of Europe Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Rest Of Europe Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
  6. Asia Pacific Oncolytic Virus Immunotherapy Market - Segment Analysis
    1. Overview
    2. Asia Pacific Oncolytic Virus Immunotherapy Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Oncolytic Virus Immunotherapy Market, by Product Type
      1. By Herpes Simplex Virus
      2. By Adenovirus
      3. By Vaccinia Virus
      4. By Vesicular Stomatitis Virus
      5. By Other Product Types
    4. Asia Pacific Oncolytic Virus Immunotherapy Market, by Application
      1. By Melanoma
      2. By Prostate Cancer
      3. By Ovarian Cancer
      4. By Lung Cancer
      5. By Breast Cancer
      6. By Other Applications
    5. Asia Pacific Oncolytic Virus Immunotherapy Market, by End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Research Institutes
    6. Asia Pacific Oncolytic Virus Immunotherapy Market, by Country
      1. China
        1. China Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. China Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. China Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      2. Japan
        1. Japan Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Japan Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Japan Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      3. India
        1. India Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. India Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. India Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      4. South Korea
        1. South Korea Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. South Korea Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. South Korea Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      5. South East Asia
        1. South East Asia Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. South East Asia Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. South East Asia Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Rest of Asia Pacific Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
  7. Latin America Oncolytic Virus Immunotherapy Market - Segment Analysis
    1. Overview
    2. Latin America Oncolytic Virus Immunotherapy Market, 2016 - 2028 (USD Million)
    3. Latin America Oncolytic Virus Immunotherapy Market, by Product Type
      1. By Herpes Simplex Virus
      2. By Adenovirus
      3. By Vaccinia Virus
      4. By Vesicular Stomatitis Virus
      5. By Other Product Types
    4. Latin America Oncolytic Virus Immunotherapy Market, by Application
      1. By Melanoma
      2. By Prostate Cancer
      3. By Ovarian Cancer
      4. By Lung Cancer
      5. By Breast Cancer
      6. By Other Applications
    5. Latin America Oncolytic Virus Immunotherapy Market, by End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Research Institutes
    6. Latin America Oncolytic Virus Immunotherapy Market, by Country
      1. Brazil
        1. Brazil Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Brazil Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Brazil Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      2. Argentina
        1. Argentina Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Argentina Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Argentina Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      3. Rest of Latin America
        1. Rest of Latin America Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Rest of Latin America Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Rest of Latin America Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
  8. Middle East & Africa Oncolytic Virus Immunotherapy Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Oncolytic Virus Immunotherapy Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Oncolytic Virus Immunotherapy Market, by Product Type
      1. By Herpes Simplex Virus
      2. By Adenovirus
      3. By Vaccinia Virus
      4. By Vesicular Stomatitis Virus
      5. By Other Product Types
    4. Middle East & Africa Oncolytic Virus Immunotherapy Market, by Application
      1. By Melanoma
      2. By Prostate Cancer
      3. By Ovarian Cancer
      4. By Lung Cancer
      5. By Breast Cancer
      6. By Other Applications
    5. Middle East & Africa Oncolytic Virus Immunotherapy Market, by End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Research Institutes
    6. Middle East & Africa Oncolytic Virus Immunotherapy Market, by Country
      1. GCC Countries
        1. GCC Countries Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. GCC Countries Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. GCC Countries Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      2. South Africa
        1. South Africa Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. South Africa Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. South Africa Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Oncolytic Virus Immunotherapy Market, By Product Type
          1. By Herpes Simplex Virus
          2. By Adenovirus
          3. By Vaccinia Virus
          4. By Vesicular Stomatitis Virus
          5. By Other Product Types
        2. Rest of Middle East & Africa Oncolytic Virus Immunotherapy Market, By Application
          1. By Melanoma
          2. By Prostate Cancer
          3. By Ovarian Cancer
          4. By Lung Cancer
          5. By Breast Cancer
          6. By Other Applications
        3. Rest of Middle East & Africa Oncolytic Virus Immunotherapy Market, By End User
          1. By Hospitals
          2. By Specialty Clinics
          3. By Cancer Research Institutes
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Sorrento Therapeutics Inc. (U.S.)
    2. Merck & Co. Inc. (U.S.)
    3. Amgen Inc. (U.S.)
    4. Shanghai Sunway Biotech Co. Ltd. (China)
    5. Cold Genesys Inc. (U.S.)
    6. Oncolytics Biotech Inc. (Canada)
    7. Transgene Biotek Ltd. (India)
    8. SillaJen Inc. (South Korea)
    9. ORYX GmbH & Co. KG (Germany)
    10. Viralytics Ltd. (Australia)
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
FAQ
Frequently Asked Question
  • The global Oncolytic Virus Immunotherapy valued at USD 100 Million in 2022 and is expected to reach USD 615.39 Million in 2030 growing at a CAGR of 25.5%.

  • The prominent players in the market are Sorrento Therapeutics Inc. (U.S.), Merck & Co. Inc. (U.S.), Amgen Inc. (U.S.), Shanghai Sunway Biotech Co. Ltd. (China), Cold Genesys Inc. (U.S.), Oncolytics Biotech Inc. (Canada), Transgene Biotek Ltd. (India), SillaJen Inc. (South Korea), ORYX GmbH & Co. KG (Germany), Viralytics Ltd. (Australia).

  • The market is project to grow at a CAGR of 25.5% between 2023 and 2030.

  • The driving factors of the Oncolytic Virus Immunotherapy include

    • Rising incidences of cancer and growing cases of Genetic diseases

  • North America was the leading regional segment of the Oncolytic Virus Immunotherapy in 2022.